Downregulation of HBx mRNA in HepG2.2.15 cells by small interfering RNA

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 12, 2007, Pages 1114-1118

  Jiao, Jing ^a   Cao, Hong ^a   Chen, Xiao Wei ^a   Zhou, Mei Juan ^a   Liu, Zhi Hua ^b   Ding, Zhen Hua ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B virus x protein; HepG2.2.15 cells; Real time reverse transcript PCR; RNA interference; Small interfering RNA; Western blot

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; MESSENGER RNA; RNA DERIVATIVE; SMALL INTERFERING RNA; SMALL INTERFERING RNA 2; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL SELECTION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HEPATOBLASTOMA; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS GENE; WESTERN BLOTTING;

BLOTTING, WESTERN; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA, VIRAL; TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 36248992987     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282748ee2     Document Type: Article

References (32)

1. Jay HH, Edward D, Jake Liang T, Russell F, Anna SFL. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45:1056-1075.
2. Hollinger FB, Liang TJ. Hepatitis B virus. In: Knipe DM, Howley PM, Chanock RM, Monath TP, Roizman B, Straus SE, editors. Field's virology. 4th ed. Philadelphia: Lippincott-Raven Publishers; 2000. pp. 2971-3036.
3. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32:828-834.
4. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang T-T, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-2681.
5. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44:283-290.
6. Chang T-T, Gish RG, de Man R, Gadano A, Sollano J, Chao Y-C, et al., for the BEHoLD A1463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
7. Doo E, Liang TJ. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001; 120:1000-1008.
8. Van Nunen AB, Janssen HL, Wolters LM, Niesters HG, de Man RA, Schalm SW. Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug? Antiviral Res 2001; 52:139-146.
9. Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354:1807-1812.
10. Lai C-L, Shouval D, Lok AS, Chang T-T, Cheinquer H, Goodman Z, et al., for the BEHoLD A1463027 Study Group. Entecavir for HBeAg-negative chronic hepatitis B. A randomized comparison of entecavir to lamivudine for treatment of HBeAg-negative chronic hepatitis B in nucleoside-naive patients. N Engl J Med 2006; 354:1011-1020.
11. Hamasaki K, Nakao K, Matsumoto K, Ichikawa T, Ishikawa H, Eguchi K. Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett 2003; 543:51-54.
12. Ying C, de Clercq E, Neyts J. Selective inhibition of hepatitis B virus replication by RNA interference. Biochem Biophys Res Commun 2003; 309:482-484.
13. Zhu MC, Fan XG, Li N, Ying RS. Inhibition of hepatitis B virus replication by RNA interference in vitro. Zhong hua Gan Zang Bing Za Zhi 2004; 12:522-525.
14. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21:639-644.
15. Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci U S A 2005; 102:773-778.
16. Wu HL, Huang LR, Huang CC, Lai HL, Liu CJ, Huang YT, et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology 2005; 128:708-716.
17. Chisari FV. Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Top Microbiol Immunol 1996; 206:149-173.
18. Andrisani OM, Barnabas S. The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis [review]. Int J Oncol 1990; 15:373-379.
19. Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Brechot C. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999; 18:4848-4859.
20. Terradillos O, Pollicino T, Lecoeur H, Tripodi M, Gougeon ML, Tiollais P, Buendia MA. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 1998; 17:2115-2123.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
22. Murakami S. Hepatitis B virus X protein: a multifunctional viral regulation. J Gastroenterol 2001; 36:651-660.
23. Hannon GJ. RNA interference. Nature 2002; 418:244-251.
24. Cullen BR. Antiviral defense and genetic tool. Nat Immunol 2002; 3:597-599.
25. Zhao ZF, Yang H, Han DW, Zhao LF, Zhang GY, Zhang Y, Liu MS. Inhibition of hepatitis B virus expression and replication by RNA interference in HepG2.2.15. World J Gastroenterol 2006; 12:6046-6049.
26. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64:51-68.
27. Ding J, Liu J, Xue CF, Gong WD, Li YH, Zhao Y. Anti-HBV effect of TAT-HBV targeted ribonuclease. World J Gastroenterol 2003; 9:1525-1528.
28. Romero MR, Martinez-Diez MC, Larena MG, Macias RI, Dominguez M, Garcia-Monzon C, et al. Evidence for dual effects of DNA-reactive bile acid derivatives (Bamets) on hepatitis B virus life cycle in an in-vitro replicative system. Antiviral Chem Chemother 2002; 13:371-380.
29. Liu J, Li YH, Xue CF, Ding J, Gong WD, Zhao Y, Hung YX. Targeted ribonuclease can inhibit replication of hepatitis B virus. World J Gastroenterol 2003; 9:295-299.
30. Tan TM, Zhou L, Houssais S, Seet BL, Jaenicke S, Peter F, Lim SG. Intracellular inhibition of hepatitis B virus S gene expression by chimeric DNA-RNA phosphorothioate minimized ribozyme. Antisense Nucleic Acid Drug Dev 2002; 12:257-264.
31. Sood RK, Bhadti VS, Fattom AI, Naso RB, Korba BE, Kern ER, et al. Novel ring-expanded nucleoside analogs exhibit potent and selective inhibition of hepatitis B virus replication in cultured human hepatoblastoma cells. Antiviral Res 2002; 53:159-164.
32. Ying C, de Clercq E, Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat 2000; 7:79-83.